Decentralized trials provider Science 37 is deepening its presence in the Asia-Pacific region with an expansion into China and Russia.

After a decades-long tenure as the so-called father of synthetic biology, George Church, Ph.D., has developed something of a Midas touch when it comes to biotech and medtech startups.

With GlaxoSmithKline, Pfizer and others in the running, Johnson & Johnson may need excellent data to capture the RSV vaccine market. The Big Pharma gave a further show of its credentials on Tuesday by sharing additional data from a study of thousands of seniors.

In what has become a near-annual tradition for Freenome, the developer of a liquid biopsy platform for early cancer detection closed yet another venture capital megaround, sending its total fundraising tally surging to more than $800 million in just seven years.

Are the foundations of Merck’s broad HIV development program crumbling? Having already paused combination work in response to a red flag, Merck has now temporarily stopped enrollment in phase 3 studies that are testing the backbone of its HIV strategy as a monotherapy.

Aslan Pharmaceuticals is ready to hit go on decentralized clinical trials after the uncertainty of the COVID-19 pandemic forced it into pausing one of its trials for about four months. Now, three months after reporting data from the restarted phase 1 trial for its Dupixent rival hopeful, the biotech is partnering with IQVIA Biotech to handle logistics related to decentralized trials.

As fast as COVID-19’s omicron variant is predicted to spread, diagnostics companies hope to be faster by quickly developing new tests to detect the coronavirus’ newest mutations.

As scientists and biopharma companies like Biogen pursue novel approaches to Alzheimer’s disease, other research teams are seeking to repurpose existing drugs to treat the disease—and using cutting-edge computational tools to uncover promising candidates. Now, one of those teams, from the Cleveland Clinic, is reporting it has found a potential Alzheimer’s treatment in one of the world’s most famous drugs: Pfizer’s erectile dysfunction treatment Viagra (sildenafil).

RefleXion Medical is aiming to develop radiation therapy capable of destroying metastatic tumors—by using the cancer itself as a tour guide through the areas of the body where it has already spread.

Scientists have known about rare and common genetic variants that influence cardiovascular disease, but few gene mutations have been found to impact more than one risk for coronary artery disease. That gap in knowledge has limited the development of new treatments targeted to individual risk factors.